Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-152 · 1 trial · 1 indication
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| Arm | Type | Description |
|---|---|---|
| Part 1: Placebo | PLACEBO_COMPARATOR | - |
| Part 1 Cohort 1A: TC | EXPERIMENTAL | - |
| Part 1 Cohort 1B: TC | EXPERIMENTAL | - |
| Part 1 Cohort 1C: TC | EXPERIMENTAL | - |
| Part 2 Cohort 2A: TEZ/IVA | ACTIVE_COMPARATOR | - |
| Part 2 Cohort 2A: TC | EXPERIMENTAL | - |
| Part 2 Cohort 2B: TEZ/IVA | ACTIVE_COMPARATOR | - |
| Part 2 Cohort 2B: TC | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VX-152 | DRUG | Tablet for oral administration. |
| TEZ/IVA | DRUG | Fixed-dose combination tablet for oral administration. |
| IVA | DRUG | Tablet for oral administration. |
| Placebo | DRUG | Placebo matched to VX-152. |
Inclusion Criteria: * Willing and able to comply with scheduled visits, treatment pan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures. * Body weight ≥35 kg. * Sweat chloride value ≥ 60 mmol/L from test results obtained during screening. * Subjects must ha...
Top 6 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | Alyftrek, Trikafta, Ivacaftor, VX-581, VX-272 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Roivant Sciences Ltd. | ROIV | 1 | PHASE1 | SP-101 |
VX-152 is an investigational small molecule developed by Vertex Pharmaceuticals for the treatment of cystic fibrosis, a respiratory disease. It was studied as part of a combination therapy regimen in adults with cystic fibrosis. VX-152 has not been approved and remains in clinical development.
VX-152 is being developed by Vertex Pharmaceuticals Incorporated, which trades on the Nasdaq under the ticker VRTX. Vertex is the sponsor of the clinical program evaluating VX-152 in cystic fibrosis.
VX-152 is in Phase 2 development. Its single recorded trial, NCT02951195, was a Phase 2 study that has been completed. VX-152 is investigational and has not been approved for any indication.
VX-152 has been evaluated in one clinical trial, NCT02951195, titled A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis. The Phase 2 trial enrolled 80 participants in the United States, was randomized, double-blind, and placebo-controlled, and is now completed.
The Phase 2 trial NCT02951195 enrolled 80 adults aged 18 years and older with cystic fibrosis in the United States. It was a randomized, double-blind, placebo-controlled study, and participants were selected based on a biomarker. The trial has been completed.